Global Dengue Vaccines Market Share, Global Trends, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2016-2026 Future Market Insights www.futuremarketinsights.com [email protected] Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends. We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client. Research Capabilities Sector Coverage Customized Research Syndicated Research Investment Research Social Media Research Automotive and Transportation Electronics, Semiconductor, and ICT Retail and Consumer Products Industrial Automation and Equipment Customized Research Subscription Information Syndicated Research For detailed subscription information please contact Investment Research T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268 Social Media Research Hari. T (Sr. Manager - Global Business Development) Email: [email protected] Chemicals & Materials Food and Beverages Services and Utilities Energy, Mining, Oil, and Gas Report Description Report Description Dengue is a mosquito-born flavivirus disease and causes dengue fever characterized by severe headache, skin rash, debilitating muscle, joint pain leaving a feverish feeling. The dengue virus is also called as ‘breakbone fever’ due to the symptoms it causes. The symptoms for dengue start appearing in the span of 3-14 days and can infect infants, young children and adults. Dengue has emerged as one of the critical vector-borne diseases especially in tropical and subtropical regions of the world. The first dengue vaccine, Dengvaxia (CYD-TDV) developed by Sanofi Pasteur registered in Mexico in December, 2015. CYD-TDV vaccine is a live recombinant tetravalent dengue vaccine which was evaluated as a 3 dose series 0/6/12 month schedule in Phase III clinical studies. There are around five other vaccine candidates under evaluation in clinical trials, comprising other live-attenuated vaccines, as well as subunit, DNA and purified inactivated vaccine candidates. Along with the developments in dengue vaccines additional technological approaches, such as virus-vectored and VLP-based vaccines, are held under evaluation in preclinical studies for further advancements. The development for dengue vaccine had begun by 1929 but was delayed due to the incomplete knowledge of the diseases. Sanofi Pasture first approved the vaccine for dengue in 2015 and integrated dengue prevention reducing the mortality rate by almost 50%. WHO Strategic Advisory Group of Experts (SAGE) on Immunization reviewed CYDTDV in April 2016 and recommended countries to introduce the vaccine through its Global dengue prevention and Control Strategy (2012-2020). Report Description Report Description Request for sample report: http://www.futuremarketinsights.com/reports/sample/repgb-1763 The drivers for dengue vaccine market include growing healthcare concerns, increase in mortality rate because of dengue fever. And the challenges faced by the scientist in developing this vaccines were majorly due to the complexity of the dengue virus, expensive trials and time to develop them. After the introduction of Dengvaxia (CYDTDV), five additional candidates are I clinical trials. The prices for dengue vaccines are much higher but due to government intervention the vaccine are sold on discounted prices in most countries. In March 2016, Dengvaxia was licensed in Mexico, the Philippines, Brazil and El Salvador for effective prevention against dengue from all four serotypes which are mostly found in individuals of age 9-45 years living in endemic areas. According to WHO (World Health Organization) dengue epidemics are being reported every year from more than 100 endemic countries causing 50-100 million dengue infections worldwide annually. In the years 2010, 2013 and 2015, nearly 2.4 million cases of dengue had been reported indicating the sharp increase in the number. It was estimated 500 000 people with severe dengue require hospitalization each year and from them 2.5% of those affected die each year. The dengue vaccine is being produced in in France in dedicated manufacturing site including a full-scale production capacity of 100 million of vaccine doses annually. Report Description Report Description In 2016, Philippines had registered to have the highest incidence of confirmed dengue among the 10 endemic countries which had participated in clinical efficacy studies for the vaccine. In April 2016, the first public dengue immunization program was started in the Philippines. The major launch event which was hosted by the Department of Health (DoH) of the Philippines, which lists the details about the country’s plan of vaccinating about 1 million public school children and was shared with the international and national press during the event. Where in February, Sanofi Pasteur’s dengue vaccine was firstly made available for the private sector vaccination in the Philippines Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1763 In the history of global burden of diseases, dengue which bears about 70% of it had an optimism after the first approval of the vaccine. Due to the developments in the recent years, pharmaceutical companies have started making effort in developing dengue vaccine and have registered their products for clinical trials. Companies such as GlaxoSmithKline plc, Merck & Co., Inc. and Takeda Pharmaceutical Company Ltd. are each at different stages in developing the vaccines for dengue. Thank You! To know more about us, please visit our website: www.futuremarketinsights.com For sales queries or new topics email us on: [email protected] Future Market Insights: 616 Corporate Way, Suite 2-9018, Valley Cottage, NY 10989, United States T: +1-347-918-3531 | D: +1-845-579-5705
© Copyright 2024